Basic research in molecular targeting therapy of malignant gliomas against NF-kB
Basic research in molecular targeting therapy of malignant gliomas against NF-kB
批准号:
15591513
负责人:
KURIMOTO Masanori
金额:
$1.79万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2004
中文摘要
点击翻译按钮获取中文摘要
英文摘要
It has been reported that NF-kB (nudear factor-kB) is a transcription factor, which controls cell proliferation of many kinds of cancer cells. This factor in inactive form is translocated in the cytoplasm and once activated by radiation or chemotherapeutic agent, NF-kB translocates into nucleus to prevent apoptosis. The authors previously reported that NF-kB is constitutively activated in malignant glioma cells, and inhibition of NF-kB resulted in the growth inhibition of the cultured human glioma cells. Therefore, the authors assume that NF-kB is the potential molecular target in the treatment strategy of malignant gliomas.This study investigated the relationship between the immunohistochemical finding of activated NF-kB and Mib-1 staining index using human glioma specimin. In addition, change of the radiation sensitivity of malignant glioma cell line (A172) by anti-NF-kB drug (pitavastatin) was analysed using MTT assay. The presence of activated form of NF-kB was confirmed by nuclear … More localization in all glioma specimin. Normal brain tissue was negative for activated form of NF-kB. Intensity of the activated form of NF-kB staining was correlated with Mib-1 staining index. This finding suggested that constitutive activation of NF-kB in gliomas were associated with growth potential. Radiation sensitivity of cultured glioma cell line (A172) was enhanced by anti-NF-kB (pitavastatin) pretreatment Pitavastatin at the concentration of 100μM was not inhibitory to A172 cells in monolayer culture, but it enhanced radiation sensitivity of A172 cells by MTT assay. Sensitization enhancement ratio was 5. Immunoblotting of the activated form of NF-kB (p50) was performed using nuclear rich lysate of cultured A172 cells. Activated form of NF-kB (p50) rapid ly increased in control A172 cells ater exposure to 15Gy radiation. However, pretreatment of A172 cells at the concentration of 100μM resulted in no increase of the activated form of NF-kB (p50). This finding may be important in the mechanism of radiosensitization of glioma cells by anti-NF-kB drug pitavastatin.In conclusion, our study demonstrate that NF-kB is constitutively activated in all of the glioma cells. Inhibition of N-kB is effective both inhibiting glioma growth and rasiosensitization of glioma cells. Therefore, NF-kB is potential molecular target to establish the new treatment strategy for malignant gliomas. Less
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1007/s11060-004-5757-1
发表时间:
2005-09-01
期刊:
JOURNAL OF NEURO-ONCOLOGY
影响因子:
3.9
作者:
[Nagai, S, Kurimoto, M, Endo, S]
通讯作者:
Endo, S
Overcome of resistance to therapy of maliganant gliomas by induction of autophagy
-
批准号:21591866
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.83万
-
财政年份:2009
-
负责人:KURIMOTO Masanori
-
依托单位:
国内基金
海外基金
登录
查看更多内容
双模式编码的慢病毒载体转染C6 Glioma Cells的影像学研究
-
批准号:81271563
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2012
-
负责人:陈正光
-
依托单位:
胶质瘤中miR-93的转录调控及其促细胞周期进展的新机制
-
批准号:81101915
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2011
-
负责人:张安玲
-
依托单位:
解析miR-566调控VHL/β-catenin信号通路影响人脑胶质瘤血管新生的分子机制
-
批准号:81101916
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:周旋
-
依托单位:
胶质瘤中miR-23b介导ICAT负调控β-catenin/TCF4信号通路的新机制
-
批准号:81001128
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2010
-
负责人:韩磊
-
依托单位:
基因修饰的人脐带间充质干细胞治疗胶质瘤的实验研究
-
批准号:81001009
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2010
-
负责人:范存刚
-
依托单位:
人脑胶质瘤Aurora A基因作用及其分子机制的研究
-
批准号:81072082
-
项目类别:面上项目
-
资助金额:33.0万元
-
批准年份:2010
-
负责人:夏之柏
-
依托单位:
胶质瘤中AKT/β-catenin信号转导通路转录调控miR-21的新机制
-
批准号:30971136
-
项目类别:面上项目
-
资助金额:32.0万元
-
批准年份:2009
-
负责人:康春生
-
依托单位:
生物信息学筛选的miRNA对SEPT7的调控与胶质瘤恶性表型的关系研究
-
批准号:30872985
-
项目类别:面上项目
-
资助金额:31.0万元
-
批准年份:2008
-
负责人:贾志凡
-
依托单位:
双向磷酸化调节P38MAPK信号通路在榄香烯抗脑胶质瘤增殖中的作用
-
批准号:30740027
-
项目类别:专项基金项目
-
资助金额:10.0万元
-
批准年份:2007
-
负责人:徐英辉
-
依托单位:
Thalidomide增强temozolomide对恶性胶质瘤治疗作用潜在机理的研究
-
批准号:30772228
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2007
-
负责人:杨学军
-
依托单位: